FDA OKs Akorn’s betamethasone lotion

The FDA approves Akorn’s (NASDAQ:AKRX) betamethasone dipropionate lotion USP (augmented), 0.05%, a topical corticosteroid for the treatment of inflammatory skin conditions.

Per IQVIA, the U.S. market is ~$10M.

Shares up 6% after hours.

https://seekingalpha.com/news/3505625-fda-oks-akorns-betamethasone-lotion